Haleon's dual-placement strategy for Advil and TUMS at CVS lifted first-quarter sales per store, and talks with Walmart are ...

FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

Companies are responding to patent cliffs and the increased cost of research and development for more complex products.

Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Oncology spending may hit $441B by 2029 as growth slows from generics—see 5 underappreciated cancer stocks with catalysts and ...

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

The capital markets increasingly favor innovative pharmaceutical assets that can sustainably generate value, and ...

One company is growing a commercial drug business with limited margin for error on the path to profitability. The other has a ...

Merck Announce Clinical Collaboration and Supply Agreement to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors CI Sep. 14 Perspective Therapeutics ...